NASDAQ:PRQR - ProQR Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.86
  • Forecasted Upside: 306.55 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$7.59
▲ +0.4 (5.56%)
1 month | 3 months | 12 months
Get New ProQR Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRQR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRQR

Average Price Target: $30.86
▲ +306.55% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for ProQR Therapeutics in the last 3 months. The average price target is $30.86, with a high forecast of $44.00 and a low forecast of $20.00. The average price target represents a 306.55% upside from the last price of $7.59.

Buy

The current consensus among 6 polled investment analysts is to buy stock in ProQR Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/20/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2021Stifel NicolausInitiated CoverageBuy$20.00Medium
3/25/2021CitigroupBoost Price Target$33.00 ➝ $44.00Medium
3/25/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price TargetBuy$33.00 ➝ $44.00High
3/24/2021Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$22.00 ➝ $33.00High
3/24/2021JMP SecuritiesBoost Price TargetOutperform$19.00 ➝ $35.00High
10/9/2020Cantor FitzgeraldReiterated RatingOverweightHigh
10/1/2020Cantor FitzgeraldReiterated RatingOverweightLow
8/11/2020Chardan CapitalLower Price TargetBuy$25.00 ➝ $20.00High
7/21/2020Chardan CapitalReiterated RatingBuy$25.00High
7/21/2020HC WainwrightReiterated RatingBuy$20.00High
6/23/2020Chardan CapitalReiterated RatingBuy$25.00Low
5/11/2020HC WainwrightReiterated RatingBuyHigh
4/1/2020Chardan CapitalReiterated RatingBuy$25.00High
10/11/2019Chardan CapitalReiterated RatingBuy$25.00High
10/10/2019CitigroupBoost Price TargetBuy$34.00 ➝ $40.00High
8/16/2019Chardan CapitalSet Price TargetBuy$25.00High
8/11/2019Royal Bank of CanadaReiterated RatingBuy$27.00Medium
3/12/2019Chardan CapitalReiterated RatingBuy ➝ Buy$21.00 ➝ $25.00High
2/28/2019HC WainwrightReiterated RatingBuy$20.00Medium
1/29/2019Cantor FitzgeraldSet Price TargetBuy$40.00Low
1/7/2019Chardan CapitalReiterated RatingBuy$21.00High
12/19/2018Royal Bank of CanadaInitiated CoverageOutperform ➝ OutperformLow
12/13/2018Cantor FitzgeraldReiterated RatingBuy$40.00Medium
11/30/2018Cantor FitzgeraldSet Price TargetBuy$40.00High
11/15/2018CitigroupInitiated CoverageBuy ➝ Buy$32.00High
11/14/2018Cantor FitzgeraldReiterated RatingOverweightLow
11/13/2018Cantor FitzgeraldInitiated CoverageBuy$40.00High
10/30/2018HC WainwrightReiterated RatingBuy$20.00Medium
9/18/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$35.00Medium
8/13/2018Chardan CapitalReiterated RatingBuy$9.00Medium
8/9/2018HC WainwrightSet Price TargetBuy$20.00Medium
7/2/2018HC WainwrightReiterated RatingBuyLow
4/5/2018Chardan CapitalInitiated CoverageBuy$4.50Low
1/16/2018Chardan CapitalReiterated RatingNeutralLow
9/26/2017SVB LeerinkReiterated RatingOutperform$10.00 ➝ $12.00High
9/26/2017HC WainwrightReiterated RatingBuy$40.00High
9/26/2017JMP SecuritiesBoost Price TargetMkt Outperform ➝ Outperform$14.00 ➝ $20.00High
9/17/2017Chardan CapitalReiterated RatingNeutralHigh
6/20/2017HC WainwrightReiterated RatingBuy$40.00High
3/1/2017HC WainwrightReiterated RatingBuy$40.00N/A
10/31/2016Chardan CapitalReiterated RatingHold$4.50N/A
10/30/2016HC WainwrightSet Price TargetBuy$40.00N/A
10/14/2016SVB LeerinkReiterated RatingOutperform$14.00N/A
9/28/2016Janney Montgomery ScottInitiated CoverageNeutral$7.00N/A
9/6/2016JMP SecuritiesReiterated RatingBuyN/A
8/18/2016SVB LeerinkReiterated RatingBuyN/A
6/20/2016Chardan CapitalInitiated CoverageNeutral$4.50N/A
(Data available from 6/18/2016 forward)
ProQR Therapeutics logo
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Read More

Today's Range

Now: $7.59
Low: $6.87
High: $7.83

50 Day Range

MA: $6.37
Low: $5.75
High: $7.59

52 Week Range

Now: $7.59
Low: $3.40
High: $9.46

Volume

1,672,474 shs

Average Volume

2,255,878 shs

Market Capitalization

$381.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Frequently Asked Questions

What sell-side analysts currently cover shares of ProQR Therapeutics?

The following sell-side analysts have issued research reports on ProQR Therapeutics in the last year: Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, HC Wainwright, JMP Securities, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for PRQR.

What is the current price target for ProQR Therapeutics?

7 Wall Street analysts have set twelve-month price targets for ProQR Therapeutics in the last year. Their average twelve-month price target is $30.86, suggesting a possible upside of 345.9%. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell has the highest price target set, predicting PRQR will reach $44.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $20.00 for ProQR Therapeutics in the next year.
View the latest price targets for PRQR.

What is the current consensus analyst rating for ProQR Therapeutics?

ProQR Therapeutics currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRQR will outperform the market and that investors should add to their positions of ProQR Therapeutics.
View the latest ratings for PRQR.

What other companies compete with ProQR Therapeutics?

How do I contact ProQR Therapeutics' investor relations team?

ProQR Therapeutics' physical mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company's listed phone number is (188) 166-7000 and its investor relations email address is [email protected] The official website for ProQR Therapeutics is www.proqr.com.